Abstract
As a laboratory finding, antinuclear antibodies (ANAs) have provided an important focus to establish the scientific foundation of rheumatology and underpin research on autoimmunity. As a laboratory test, however, ANAs have provided uncertain and often confusing information that can drive unnecessary costs, as shown in a provocative paper by Ai Li Yeo and colleagues1 in Lancet Rheumatology. The discordancy between the scientific value of the ANA test and its real-world utility is striking given that ANA testing has been a routine part of patient evaluation for more than 50 years and has witnessed many important technological improvements.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
